ENETS consensus recommendations for the standards of care in neuroendocrine neoplasms (NEN) concerning follow-up and documentation are considered in this review. The documentation of patients with NEN should include the most relevant data characterizing an individual patient from the first contact with his/her physician/hospital until his/her last presentation during follow-up. It is advocated that follow-up occurs in specialized NEN centers with regular NEN tumor boards with expert panels. The follow-up should be in accordance with the ENETS consensus guidelines from 2011 and 2016, the present and coming WHO classification and ENETS/UICC recommendations for TNM staging. The recommendations for follow-up in patients with thymic, bronchopulmonary and gastroenteropancreatic NEN are given in Table 1. However, it should be stressed that evidence-based studies for follow-up are largely missing.

Keywords:
Neuroendocrine neoplasm, Neuroendocrine tumor, Neuroendocrine carcinoma, Follow-up, TNM staging, Chromogranin A, Neuron-specific enolase, 5-Hydroxyindoleacetic acid, NT-pro-brain natriuretic peptide, Functional imaging
1.
Bosman FT, Carneiro F, Hruban R, Theise N: WHO Classification of Tumours of the Digestive System, ed 4. Lyon, International Agency for Research on Cancer (IARC), 2010.
2.
Salazar R, Wiedenmann B, Rindi G, Ruszniewski P: ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology 2012;95:71-73.
3.
O'Toole D, Kianmanesh R, Caplin M: ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: an update. Neuroendocrinology 2016;103:117-118.
4.
Rindi G, Kloppel G, Alhman H, et al: TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
5.
Rindi G, Klöppel G, Couvelard A, Komminoth P, et al: TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-762.
6.
Arnold R, Chen YJ, Costa F, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: follow-up and documentation. Neuroendocrinology 2009;90:227-233.
7.
Caplin ME, Baudin E, Ferolla P, et al: Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 2015;26:1604-1620.
8.
Tabaksblat EM, Langer SW, Knigge U, et al: Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: state of the art. Acta Oncol 2016;55:3-14.
9.
Arnold R, Wilke A, Rinke A, et al: Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors. Clin Gastroenterol Hepatol 2008;6:820-827.
10.
Oberg K, Janson ET, Eriksson B: Tumour markers in neuroendocrine tumours. Ital J Gastroenterol Hepatol 1999;31(suppl 2):S160-S162.
11.
Janson ET, Holmberg L, Stridsberg M, et al: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685-690.
12.
Jensen KH, Hilsted L, Jensen C, et al: Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol 2013;48:70-77.
13.
Yao JC, Lombard-Bohas C, Baudin E, et al: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
14.
Yao JC, Pavel M, Phan AT, et al: Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96:3741-3749.
15.
Welin S, Stridsberg M, Cunningham J, et al: Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89:302-307.
16.
Campana D, Nori F, Piscitelli L, et al: Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007;25:1967-1973.
17.
Marotta V, Nuzzo V, Ferrara T, et al: Limitations of chromogranin A in clinical practice. Biomarkers 2012;17:186-191.
18.
Bech PR, Martin NM, Ramachandran R, Bloom SR: The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia. Ann Clin Biochem 2014;51:8-21.
19.
Baudin E, Gigliotti A, Ducreux M, et al: Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998;78:1102-1107.
20.
Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
21.
Bajetta E, Ferrari L, Martinetti A, et al: Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858-865.
22.
Tohmola N, Johansson A, Sane T, et al: Transient elevation of serum 5-HIAA by dietary serotonin and distribution of 5-HIAA in serum protein fractions. Ann Clin Biochem 2015;52:428-433.
23.
Bhattacharyya S, Jagroop A, Gujral DM, et al: Circulating plasma and platelet 5-hydroxytryptamine in carcinoid heart disease: a pilot study. J Heart Valve Dis 2013;22:400-407.
24.
Dobson R, Burgess MI, Banks M, et al: The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study. PLoS One 2013;8:e73679.
25.
Dero I, De Pauw M, Borbath I, et al: Carcinoid heart disease - a hidden complication of neuroendocrine tumours. Acta Gastroenterol Belg 2009;72:34-38.
26.
Plockinger U, Gustafsson B, Ivan D, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: echocardiography. Neuroendocrinology 2009;90:190-193.
27.
Bhattacharyya S, Toumpanakis C, Chilkunda D, et al: Risk factors for the development and progression of carcinoid heart disease. Am J Cardiol 2011;107:1221-1226.
28.
Dromain C, de Baere T, Lumbroso J, et al: Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23:70-78.
29.
Geijer H, Breimer LH: Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013;40:1770-1780.
30.
Pfeifer A, Knigge U, Mortensen J, et al: Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: first-in-humans study. J Nucl Med 2012;53:1207-1215.
31.
Pfeifer A, Knigge U, Binderup T, et al: 64Cu-DOTATATE PET for neuroendocrine tumors: a prospective head-to-head comparison with 111In-DTPA-octreotide in 112 patients. J Nucl Med 2015;56:847-854.
32.
Johnbeck CB, Knigge U, Kjaer A: PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol 2014;10:2259-2277.
33.
Santhanam P, Chandramahanti S, Kroiss A, et al: Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how? Eur J Nucl Med Mol Imaging 2015;42:1144-1155.
34.
Haug A, Auernhammer CJ, Wangler B, et al: Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2009;36:765-770.
35.
Ambrosini V, Tomassetti P, Castellucci P, et al: Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:1431-1438.
36.
Orlefors H, Sundin A, Garske U, et al: Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-3400.
37.
Wild D, Christ E, Caplin ME, et al: Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 2011;52:1073-1078.
38.
Chougnet CN, Leboulleux S, Caramella C, et al: Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy. Endocr Relat Cancer 2013;20:229-239.
39.
Binderup T, Knigge U, Loft A, et al: 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-985.
40.
Abgral R, Leboulleux S, Deandreis D, et al: Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (≥10%) well-differentiated endocrine carcinoma staging. J Clin Endocrinol Metab 2011;96:665-671.
41.
Binderup T, Knigge U, Loft A, et al: Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704-712.
42.
Kubota K, Okasaki M, Minamimoto R, et al: Lesion-based analysis of (18)F-FDG uptake and (111)In-pentetreotide uptake by neuroendocrine tumors. Ann Nucl Med 2014;28:1004-1010.
43.
Grozinsky-Glasberg S, Grossman AB, Gross DJ: Carcinoid heart disease: from pathophysiology to treatment - ‘something in the way it moves.' Neuroendocrinology 2015;101:263-273.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.